Sierra Oncology Inc (NASDAQ:SRRA) – Equities research analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for Sierra Oncology in a research report issued on Monday, March 4th. Jefferies Financial Group analyst M. Raycroft forecasts that the biotechnology company will post earnings of ($0.21) per share for the quarter. Jefferies Financial Group also issued estimates for Sierra Oncology’s FY2023 earnings at $0.13 EPS.
Get Sierra Oncology alerts:Separately, Wedbush reaffirmed an “outperform” rating on shares of Sierra Oncology in a report on Thursday, February 28th.
Shares of SRRA opened at $1.83 on Wednesday. Sierra Oncology has a 12-month low of $1.05 and a 12-month high of $3.70. The company has a quick ratio of 14.68, a current ratio of 14.68 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $146.51 million, a price-to-earnings ratio of -2.44 and a beta of 1.61.
Sierra Oncology (NASDAQ:SRRA) last issued its earnings results on Thursday, February 28th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01.
In other news, Director Andrew R. Allen bought 66,000 shares of the stock in a transaction on Monday, December 10th. The stock was acquired at an average price of $1.64 per share, with a total value of $108,240.00. Following the acquisition, the director now directly owns 66,000 shares in the company, valued at $108,240. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.61% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC grew its position in shares of Sierra Oncology by 5.4% in the 4th quarter. Acadian Asset Management LLC now owns 407,105 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 20,754 shares during the last quarter. Bridgeway Capital Management Inc. grew its position in shares of Sierra Oncology by 36.9% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 225,000 shares of the biotechnology company’s stock valued at $383,000 after buying an additional 60,700 shares during the last quarter. Morgan Stanley grew its position in shares of Sierra Oncology by 11.3% in the 3rd quarter. Morgan Stanley now owns 992,516 shares of the biotechnology company’s stock valued at $1,687,000 after buying an additional 100,709 shares during the last quarter. Hikari Power Ltd bought a new stake in shares of Sierra Oncology in the 4th quarter valued at about $330,000. Finally, Algert Global LLC grew its position in shares of Sierra Oncology by 173.8% in the 3rd quarter. Algert Global LLC now owns 394,258 shares of the biotechnology company’s stock valued at $670,000 after buying an additional 250,267 shares during the last quarter. Hedge funds and other institutional investors own 60.61% of the company’s stock.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Featured Article: Google Finance Portfolio Tips and Tricks
No comments:
Post a Comment